Research Topics
| Luis RuilopeSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
Blood pressure lowering or selection of antihypertensive agent: which is more important?Luis M Ruilope
Nephrol Dial Transplant 21:843-5. 2006
Blood pressure control in patients with comorbiditiesRoland E Schmieder
Department of Nephrology and Hypertension, University Hospital Erlangen, Erlangen, Germany
J Clin Hypertens (Greenwich) 10:624-31. 2008..Not all available antihypertensives are equally effective in controlling BP over 24 hours, and some may exacerbate underlying metabolic abnormalities...
Renal participation in cardiovascular risk in essential hypertensionLuis M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
Expert Rev Cardiovasc Ther 1:309-15. 2003....
Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidityLuis M Ruilope
, Hospital 12 de Octubre, Madrid, Spain
Curr Hypertens Rep 4:261-4. 2002
Renal protection by antihypertensive therapyLuis M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
Curr Hypertens Rep 4:324-8. 2002..The control of other associated risk factors is also required, in particular smoking and lipids...
ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?Luis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, 28041, Spain
J Renin Angiotensin Aldosterone Syst 4:74-9. 2003..All these facts led to the conclusion that both ACE-Is and ARBs can be considered when both renal and cardiovascular protection are aimed for in Type 2 diabetic patients...
The kidney as a sensor of cardiovascular risk in essential hypertensionLuis M Ruilope
Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
J Am Soc Nephrol 13:S165-8. 2002..Prevention and protection of renal and cardiovascular damage in these patients will be one of the most relevant tasks in the future...
Eprosartan for the treatment of hypertensionLuis Ruilope
Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
Expert Opin Pharmacother 4:107-14. 2003..Eprosartan is safe, effective and well-tolerated in long-term treatment, either as a monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide...
Cardiovascular therapy in patients with renal insufficiencyLuis M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
Cardiovasc Drugs Ther 16:497-501. 2002..Besides this, strict control of associated cardiovascular risk factors is also required...
Lessons from trials in hypertensive type 2 diabetic patientsLuis M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
Curr Hypertens Rep 5:322-8. 2003..However, by attaining normal blood pressure levels (< 130/80 mm Hg), better preservation of glomerular filtration rate does not seem to be insured...
New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal diseaseL M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
J Renin Angiotensin Aldosterone Syst 1:S29-31. 2000..Unlike ACE inhibition, ARB treatment leads to no initial reduction in GFR, thus valsartan may be a better agent for the control of BP, with greater renal protection...
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidenceLuis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Clin Ther 25:3044-64. 2003..Preventing or delaying the progression of renal disease from microalbuminuria to nephropathy, and ultimately, to ESRD is thus a crucial goal of DM management...
Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?Luis M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
Blood Press 11:106-9. 2002..The results from INSIGHT support incorporating nifedipine GITS in the management of high-risk hypertensive patients to prevent atherosclerosis-related illness and death...
Kidney dysfunction: a sensitive predictor of cardiovascular riskL M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
Am J Hypertens 14:213S-217S. 2001..The parameters commonly used to evaluate renal function have to be considered in any stratification of cardiovascular risk in hypertensive and heart failure patients...
Hyperuricemia and renal functionL M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, 28041, Madrid, Spain
Curr Hypertens Rep 3:197-202. 2001..For this reason, the predictive capacity of uric acid could be partly dependent on the fact that hyperuricemia runs in parallel with a deranged renal function...
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) studyL M Ruilope
Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
J Am Soc Nephrol 12:218-25. 2001....
The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue?L M Ruilope
Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
Curr Hypertens Rep 3:419-21. 2001....
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal DiseaseL M Ruilope
Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain
J Hypertens 18:89-95. 2000..Such enhanced suppression might be of benefit for patients exhibiting a progressive decline in renal function because of chronic renal disease...
Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use?L M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
Hypertension 38:537-42. 2001..The question remains for the time being largely unanswered...
Renal function: the Cinderella of cardiovascular risk profileL M Ruilope
Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
J Am Coll Cardiol 38:1782-7. 2001..Renal outcome is also improved by ACE inhibition after an MI. Finally, renal and cardiovascular outcome seem to run in parallel in all these situations...
Renal participation in cardiovascular risk in essential hypertensionL M Ruilope
Unit of Hypertension, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain
Blood Press 10:322-6. 2001..Prevention and protection of renal and cardiovascular damage in these patients will be one of the most relevant healt care tasks in the future...
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?Luis Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
J Clin Hypertens (Greenwich) 12:422-30. 2010....
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of HypertensionLuis Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Blood Press 16:72-9. 2007....
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyHermann Haller
Nephrology Section, Hanover Medical School, Hanover, Germany
J Hypertens 24:403-8. 2006..The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease...
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST studyLuis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
Clin Ther 27:578-87. 2005..Recent antihypertensive treatment guidelines recommend greater use of combination therapies...
Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular riskJulian Segura
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Fundam Clin Pharmacol 19:429-37. 2005..The high prevalence of chronic kidney disease in the general and in the hypertensive populations implies the need for an integrative therapeutic approach to fully protect renal and cardiovascular systems simultaneously...
Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax)Luis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
J Hypertens Suppl 24:S9-12. 2006..The fixed combination of perindopril/indapamide can greatly help clinicians in achieving the above goals, using Preterax in the early and BiPreterax in the late stages of nephropathy...
Chronic kidney disease as a situation of high added risk in hypertensive patientsJulian Segura
Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, 28041 Madrid, Spain
J Am Soc Nephrol 17:S136-40. 2006..This paper briefly reviews the most recent evidences about pharmacologic therapies in high-risk patients, focusing on benefits related to improvement of cardiovascular risk factors in hypertensive patients with chronic kidney disease...
Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathiesPedro Aranda
Nephrology Department, Hospital Regional Universitario Carlos Haya, , Spain
Am J Kidney Dis 46:1074-9. 2005..CONCLUSION: Long-term administration of high doses of telmisartan seems to improve the efficacy of the drug to decrease proteinuria and slow the progression to end-stage renal failure in nondiabetic hypertensive renal disease...
Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional studyRafael Marín
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
J Hypertens 24:395-402. 2006..The present study was designed for assessment of control rates of blood pressure in patients with CRI. Secondary objectives included evaluation of the control rates of proteinuria and cardiovascular comorbidities...
Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus MeetingPaolo Palatini
Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy
J Hypertens 24:603-10. 2006
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuriaGeorge L Bakris
Rush University Medical Center, Chicago, Illinois 60612, USA
J Hypertens 24:2047-55. 2006..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trialLuis M Ruilope
Internal Medicine, Comlutense University, Madrid, Spain
J Renin Angiotensin Aldosterone Syst 7:S8-11. 2006..In addition, combination therapy resulted in a trend towards more favourable outcomes with respect to pro-thrombotic and proinflammatory markers than amlodipine alone...
The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapyLuis M Ruilope
Servicio de Nefrologia, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Clin Exp Hypertens 30:397-414. 2008..ARBs decrease overall risk of CV and end-organ disease, CVD-related mortality, and cerebrovascular events in patients with hypertension...
Angiotensin receptor blockers: RAAS blockade and renoprotectionLuis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Curr Med Res Opin 24:1285-93. 2008..The central role of the renin-angiotensin-aldosterone system (RAAS) in hypertension and renal disease has led to interest in the ability of RAAS-blocking agents to provide benefits beyond blood pressure control...
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study resultsLuis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
J Hypertens 26:357-67. 2008..This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with similar design - the Rimonabant-In-Obesity (RIO) programme...
Glucose metabolism in patients with essential hypertensionJuan Garcia-Puig
Division of Internal Medicine at Hospital Universitario La Paz, Madrid, Spain
Am J Med 119:318-26. 2006..Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension...
Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?Julian Segura
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Curr Opin Nephrol Hypertens 16:422-6. 2007....
Trandolapril/verapamil combination in hypertensive diabetic patientsJose A Garcia Donaire
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Vasc Health Risk Manag 3:77-82. 2007..This combination can be considered as an effective therapy for the diabetic hypertensive population...
Angiotensin receptor blockade in diabetic renal disease--focus on candesartanJose A Garcia Donaire
Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
Diabetes Res Clin Pract 76:S22-30. 2007..When given in addition to an ACE inhibitor (dual blockade), reductions in UAE of 25-35% relative to ACE inhibitor monotherapy have been found...
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetesRoland E Schmieder
Department of Nephrology and Hypertension, University of Erlangen Nurnberg, Erlangen, Germany
Diabetes Care 30:1351-6. 2007..The aim of this study was to analyze the effects of renin-angiotensin system (RAS) blockade on renal endothelial function...
Clinical trials in nephrology: success or failureJose A Garcia Donaire
Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
Curr Opin Nephrol Hypertens 16:59-63. 2007..Suppression of the rennin-angiotensin-aldosterone system should also be considered in any patient with chronic kidney disease, in particular if albuminuria is present...
Obesity, essential hypertension and renin-angiotensin systemJulian Segura
Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
Public Health Nutr 10:1151-5. 2007..This review discusses the role of RAS in the relationship between obesity, essential hypertension and insulin resistance...
Left ventricular hypertrophy and clinical outcomes in hypertensive patientsLuis M Ruilope
Hospital 12 de Octubre, Avda de Cordoba s n, Madrid, Spain
Am J Hypertens 21:500-8. 2008..Guidelines, therefore, have recommended these drug classes for the treatment of hypertensive patients with LVH...
Calcium channel blockers and renal protection: insights from the latest clinical trialsJulian Segura
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
J Am Soc Nephrol 16:S64-6. 2005....
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-studyLuis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain bNovartis AG, Basel, Switzerland
Blood Press Monit 10:85-91. 2005..There is a lack of data on the effects of angiotensin-receptor blocker and diuretic combinations on ambulatory blood pressure (ABP) in hypertensive patients with additional cardiovascular risk factors...
[PREVENCAT study: control of cardiovascular risk in primary care]Luis A Alvarez-Sala
Departamento de Medicina, , Facultad de Medicina, Universidad Complutense, Madrid, Spain
Med Clin (Barc) 124:406-10. 2005..7-52.5). CONCLUSIONS: The control of the CVRF considered in primary care attended population is insufficient. Hardly one of each 2 patients with HT, DM2 and HC is under control. The overweight and sedentarism control is still poorer...
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended dosesJuliá Segura
Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, 28041, Spain
J Renin Angiotensin Aldosterone Syst 4:43-7. 2003..Both ACE-I and ARB were titrated as monotherapy up to the maximal recommended dose...
Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT)Giuseppe Mancia
University of Milano Bicocca, St Gerardo Hospital, Monza, Milan, Italy
Hypertension 41:431-6. 2003..Our results suggest that nifedipine could be considered as first-line therapy for hypertensive diabetics...
Hypertension magnitude and management in the elderly population of SpainJose R Banegas
Department of Preventive Medicine and Public Health, Autonomous University of Madrid, Madrid, Spain
J Hypertens 20:2157-64. 2002..The present study assessed the prevalence, awareness, treatment and control of hypertension among the elderly population of Spain...
Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?Alberto Zanchetti
Centro di Fisiologia Clinica e Ipertensione, Universita di Milano, Ospedale Maggiore and Istituto Auxologico Italiano, Milano, Italy
J Hypertens 20:2099-110. 2002..Patients with type-2 diabetes have a high prevalence of hypertension and show an elevated incidence of cardiovascular events and nephropathy...
N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patientsVivencio Barrios
Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain
Blood Press 11:235-9. 2002..This effect may be mediated by an NO-dependent mechanism, probably through the protective effect of NAC on NO oxidation...
The Framingham prediction rule is not valid in a European population of treated hypertensive patientsSylvie Bastuji-Garin
Department of Public Health, Henri Mondor Hospital, AP HP, Paris XII University, Creteil, France
J Hypertens 20:1973-80. 2002..Stratification of population groups according to cardiovascular risk level is recommended for primary prevention...
Renal dysfunction as a cardiovascular risk factorEberhard Ritz
Department of Internal Medicine, University of Heidelberg, Bergheimer Strasse 58, Germany
Curr Hypertens Rep 4:365-8. 2002..Epidemiologic information suggests that renal and cardiovascular outcome run parallel in this segment of the population...
Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de SeguridadVivencio Barrios
Servicio de Cardiologia, Hospital Ramon y Cajal, Madrid, Spain
Blood Press 11:95-100. 2002..With the aim to determine the efficacy and tolerability of this drug in usual clinical practice we performed the ELYPSE trial...
ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?Luis M Ruilope
Hypertension Unit, Hospital 12 de Octubre, Complutense University, Madrid, Spain
Am J Hypertens 15:367-71. 2002....
Losartan titration versus diuretic combination in type 2 diabetic patientsPedro Luis de Pablos-Velasco
, Las Palmas de Gran Canaria, Spain
J Hypertens 20:715-9. 2002..When the blood pressure target was not reached, the two strategies tested seem to contribute similarly to further reductions in blood pressure and albuminuria...
Valsartan improves fibrinolytic balance in atherosclerotic rabbitsM Pilar Oubina
Departmento de Fisiologia, Facultad de Medicina, Universidad Complutense, Madrid, Spain
J Hypertens 20:303-10. 2002..To examine the long-term effects of the angiotensin type I (AT1) receptor antagonist, valsartan, on fibrinolytic balance, coagulation parameters, endothelial function and structural alterations in atherosclerotic rabbits...
Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitorsChristopher R Palmer
JAMA 289:2066-7; author reply 2069-70. 2003
How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?Julian Segura
Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
Curr Hypertens Rep 5:426-9. 2003..The aim of this paper is to briefly review the evidence in favor of uptitration of either class of inhibitors of the renin-angiotensin system as compared with the combination of the two for the control of either BP or proteinuria...
Recent developments in the treatment of type 2 diabetes mellitusLuis M Ruilope
Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain
Cardiovasc Drugs Ther 17:151-8. 2003..Agents that interfere with the renin-angiotensin system, particularly angiotensin-receptor blockers, may have particular benefits on end-organs in diabetic patients...
Renal endpoints in hypertension trialsHelle Christiansen
Unidad de Hipertension, Madrid, Spain
Clin Exp Hypertens 26:721-6. 2004..This paper describes the detection, prevalence and relevance of minor alterations in the stratification of cardiovascular risk in the hypertensive patient...
Hope in Life and Value of blood pressure controlLuis M Ruilope
J Hypertens 22:2265-6. 2004
Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trialPeter W de Leeuw
Department of Medicine, University Hospital Maastricht, Maastricht, The Netherlands
Arch Intern Med 164:2459-64. 2004..To assess this role of renal function in more detail, we studied the evolution of renal function and the relationship of renal function with mortality and morbidity in the Intervention as a Goal in Hypertension Treatment (INSIGHT) study...
Cerebrovascular protection and antihypertensive therapyJose A Garcia-Donaire
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Curr Opin Nephrol Hypertens 13:507-12. 2004..In addition, an overview of stroke pathogenesis is given and its relationship with treatment action mechanisms reviewed...
Development of chronic kidney disease in essential hypertension during long-term therapyJulian Segura
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Curr Opin Nephrol Hypertens 13:495-500. 2004..This review examines the relevance of the development of chronic kidney disease in long-term hypertensive patients on the cardiovascular prognosis...
Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertensionCarlos Calvo
Hypertension and Vascular Risk Unit, , Santiago de Compostela, Madrid, Spain
J Hypertens 22:837-46. 2004....
Blood pressure control and physician management of hypertension in hospital hypertension units in SpainJose R Banegas
Department of Preventive Medicine and Public Health, of Medicine, Universidad Autonoma de Madrid, Spain
Hypertension 43:1338-44. 2004..Patients at high risk, with diabetes or proteinuria, warrant focused attention. Moreover, a more aggressive behavior of doctors treating uncontrolled hypertension is needed...
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) studyLuis M Ruilope
Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
J Hypertens 22:217-22. 2004....
Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertensionCarlos Campo
Unidad de Hipertension, Departamento de Bioquimica, Hospital Universitario 12 de Octubre, Madrid, Spain
Blood Press 12:277-83. 2003..Hyperuricemia has been shown to be associated with an increased risk of cardiovascular disease in hypertensive patients in some but not in all epidemiological studies in which this relationship has been investigated...
Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertensionCarlos Campo
Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid ES 28041, Spain
Blood Press Suppl 2:16-21. 2003..Therefore, in patients not controlled with monotherapy, doxazosin GITS can be considered an alternative to the addition of thiazide diuretics...
New-onset diabetes and antihypertensive therapy: comments on ALLHAT trialCristina Sierra
Hypertension Units, Hospital Clinic of Barcelona, Madrid, Spain
J Renin Angiotensin Aldosterone Syst 4:169-70. 2003..Long-term studies are required to determine the relevance of development of new-onset diabetes in treated hypertensive patients...
Factors influencing the systolic blood pressure response to drug therapyCarlos Campo
Hypertension Unit, 12 de Octubre University Hospital, Avda de Cordoba s n, Madrid, 280041 Spain
J Clin Hypertens (Greenwich) 4:35-40. 2002..It appears that the profile of patients with a poorer therapeutic response includes a greater severity of hypertension and/or the presence of cardiovascular disease...
